Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) regularly issues detailed news releases about its work in recombinant spider silk and bioengineered fibers. The company describes itself as a world leader in spider silk technology and uses its news flow to report on production milestones, facility expansions, scientific progress, and commercial engagements.
News items often highlight advances in the company’s BAM-1 and BAM-1 Alpha hybrid silkworm lines, including selective breeding achievements that increase cocoon shell weight, throughput, and production efficiency. Kraig Biocraft Laboratories also reports on the launch and completion of spider silk production cycles, the deployment of BAM-1 Alpha as its primary production hybrid, and the integration of diapause egg management into its rearing operations.
Another recurring theme in KBLB news is the build-out of production infrastructure in Southeast Asia. Releases cover topics such as taking possession of additional silkworm rearing centers, relocating facilities to protected highlands, and maintaining multiple, parallel production sites to support scalability and resilience. The company also reports on securing usage rights to government-owned mulberry gardens and taking control of mulberry fields dedicated to its operations, emphasizing feedstock security and vertical coordination.
Investors and observers can also find updates on commercial and research developments, including pilot programs with a globally recognized performance sports apparel brand and announcements about scientific leadership and breakthroughs in advanced fibers and bioengineered materials. Together, these news items provide an ongoing view into Kraig Biocraft Laboratories’ efforts to expand spider silk production capacity, refine its technology, and pursue high-value applications in performance textiles, technical apparel, and other markets.
Kraig Biocraft Laboratories (OTCQB: KBLB) announces significant advancements via its joint venture, Spydasilk Enterprises, with Kings Group. The partnership has applied for four brand trademarks centered on spider silk technology with the US Patent and Trademark Office. These trademarks aim to enhance branding for their yarns and textiles. Additionally, Spydasilk Enterprises plans to expand its distribution network and explore markets beyond apparel, potentially increasing an exclusive agreement valued at up to US$40 million.
Kraig Biocraft Laboratories has formed a joint venture with Kings Golden Harvest, establishing Spydasilk Enterprises in Singapore. This venture is linked to a $40 million exclusive purchase and sales agreement. Spydasilk Enterprises aims to develop luxury streetwear leveraging Kraig's spider silk technology, targeting the ASEAN market. Both companies anticipate significant demand for spider silk products across various industries. This partnership is a strategic move for Kraig Labs to integrate vertically and enhance profit margins through innovative biocompatible and biodegradable fibers.
Kraig Biocraft Laboratories (KBLB) announced that the University of Notre Dame has received a Vietnamese patent for spider silk technology, enhancing KBLB's intellectual property portfolio. The patent number 26612, covering a novel chimeric spider silk polypeptide, grants KBLB exclusive global licensing rights until September 2031. This news indicates an expansion of KBLB's operational foothold in Vietnam, with ongoing applications in other jurisdictions. COO Jon Rice highlighted this as a significant achievement for both the company and their collaborating researchers.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced it has doubled its planned production of recombinant spider silk for March 2021 after a successful initial run from its Vietnam factory. The company aims to meet existing material requests and contract deliverables, particularly for M the Movement and PL Kings. Kraig Labs is also expanding its staff at Prodigy Textiles to support increased production capacity. COO Jon Rice expressed optimism about the future of the company as they prepare to bring their eco-friendly spider silk to market.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) has announced that the University of Notre Dame has been granted a Canadian patent for spider silk technology developed under a collaboration with Kraig. This patent (number 2,812,791) protects the Company’s proprietary recombinant spider silk until September 2031. Kraig Labs has agreed to cover development and patent costs for exclusive global licensing rights. The Company aims to solidify its position in the spider silk market by leveraging this new intellectual property.
Kraig Biocraft Laboratories has achieved a significant milestone by receiving its first delivery of spider silk fibers from its wholly-owned subsidiary, Prodigy Textiles, based in Vietnam. This marks a critical step in scaling up production to meet growing demand from various sectors, including sports apparel and medical products. The company anticipates fulfilling existing requests, notably from Polartec LLC and MtheMovement. Kraig Labs is transitioning from a developer to a producer of high-quality spider silk, aiming to solidify market partnerships and innovate new products.
Kraig Biocraft Laboratories (OTCQB: KBLB) has filed a patent for its advanced spider silk mass production technologies, particularly focusing on knock-in knock-out gene editing systems for nearly pure spider silk fibers. This application, titled "Modification of Heavy Chain Fibrion in Bombyx Mori," builds on a provisional patent filed in February 2020. CEO Kim Thompson stated that the filing is timely as the company intends to transition this new technology to production soon, emphasizing its core role in commercialization and sales.
Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) has successfully produced and genetically screened a new batch of spider silk silkworm eggs, ready for shipment to Vietnam to resume commercial production. Operations were halted in March due to COVID-19, during which the company enhanced its Dragon Silk strain's performance and genetics. CEO Kim Thompson praised the team's progress, emphasizing that these silkworm eggs signify the future of spider silk production.